Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel, targeted, small molecule cancer therapeutics, today announced that it will present new data on its first-in-class oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback